Quotables
"Rail travel at high speeds is not possible because passengers, unable to breathe, would die of asphyxia."
Dionysius Lardner, Professor of Natural Philosophy and Astronomy at University College, London ; 1830
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8119596 | Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use A composition for treating damaged tissue and promoting healthy tissue growth, healing and tissue regeneration, wherein said composition comprises an extracellular matrix compound, a surface-active lipid, one or more enantiomerically pure L-amino acids or glycine, a... | 02/21/2012 |
| 8114840 | Medicament containing activated antithrombin III The invention concerns the use of antithrombin III with a modified conformation which is referred to as activated antithrombin III (IDAAT=immune defense activated antithrombin) as a medicament. ... | 02/14/2012 |
| 8017577 | Lyophilizable and enhanced compacted nucleic acids Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to m... | 09/13/2011 |
| 8008252 | Factor VII: remodeling and glycoconjugation of Factor VII The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. ... | 08/30/2011 |
| 7977311 | Methods and compositions for the prevention and treatment of anemia Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to ob... | 07/12/2011 |
| 7968514 | Pharmaceutical composition for treating or preventing ovarian cancer The invention relates to therapeutic and prophylactic treatment of ovarian cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of an ovarian tissue cell-associated protein or immunological... | 06/28/2011 |
| 7951774 | Stereochemically defined dipeptide esters of antiviral agents for enhanced ocular treatment Stereochemically defined dipeptide esters of nucleoside-analogous antiviral agents including acyclovir and ganciclovir are provided. Certain of these stereochemically defined dipeptide esters are found to have unexpectedly enhanced delivery to and uptake by ocular t... | 05/31/2011 |
| 7923430 | Methods for producing modified glycoproteins Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. The lower eukaryotes, which ordinarily produce high-mannose cont... | 04/12/2011 |
| 7879799 | Methods for characterizing glycoproteins and generating antibodies for same The invention provides methods for generating an antibody specific for the deglycosylated form of a glycopolypeptide using a peptide corresponding to an N-linked glycosylation site of a glycopolypeptide. The invention additionally provides methods for generating an ... | 02/01/2011 |
| 7875585 | Hematopoietic cell E-selectin / L-selectin ligand glycosylated CD44 polypeptide The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal. ... | 01/25/2011 |
| 7858583 | Process for purifying glycopeptide phosphonate derivatives Disclosed are methods of purifying glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups that are useful as antibacterial agents. The methods include contacting a solution of the glycopeptide derivatives with a... | 12/28/2010 |
| 7851438 | Erythropoietin compositions Methods and materials are provided for the production of compositions of erythropoietin protein, wherein said compositions comprise a pre-selected N-linked glycosylation pattern as the predominant N-glycoform. ... | 12/14/2010 |
| 7846896 | PEG conjugates of NK4 The present invention provides a conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise a... | 12/07/2010 |
| 7838492 | Recombinant canine thyroid stimulating hormone and methods of production and use thereof The invention includes a nucleic acid having a sequence at least 98% homologous to SEQ ID NO: 1, which encodes the α subunit of canine thyroid stimulating hormone (TSH). The invention also includes a nucleic acid having a sequence at least 98% homologous to SEQ ID ... | 11/23/2010 |
| 7825086 | Acyclovir-peptide analogs Dipeptide and tripeptide ester derivatives of acyclovir and its analogs are disclosed which are useful to treat herpes virus infections. Also disclosed is a method for preparing a therapeutic agent for targeted delivery to ocular tissue comprising linking the therap... | 11/02/2010 |
| 7825085 | Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells The present invention relates generally to peptides derived from the natural cytotoxicity receptors on natural killer (NK) cells and to antibodies against peptide epitopes on these receptors. In particular, the present invention identifies an essential epitope in th... | 11/02/2010 |
| 7807636 | Bovine P-selectin glycorpotein ligand-1 A novel bovine P-selectin glycoprotein ligand-1 (bPSGL-1) is disclosed having the amino acid sequence set forth in SEQ. ID. NO:1. DNA sequences encoding the bPSGL-1 are also disclosed, along with vectors, host cells, and methods of using the bPSGL-1. The inve... | 10/05/2010 |
| 7803764 | Amphipathic glycopeptides Amphipathic glycopeptides, the amino acid sequence of which comprises an N-terminal opioid message sequence, a C-terminal helical address sequence, and a linker sequence between the message sequence and the helical address sequence, where the C-terminal helical addr... | 09/28/2010 |
| 7799755 | Immunomodulatory methods using oligosaccharides Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokin... | 09/21/2010 |
| 7795210 | Protein remodeling methods and proteins/peptides produced by the methods The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. ... | 09/14/2010 |
| 7790679 | Pharmaceutical formulations A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing co... | 09/07/2010 |
| 7790678 | Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use A composition for treating damaged tissue and promoting healthy tissue growth, healing and tissue regeneration, wherein said composition comprises an extracellular matrix compound, a surface-active lipid, one or more enantiomerically pure L-amino acids or glycine, a... | 09/07/2010 |
| 7776821 | Method comprising nanofiltration to obtain an MBL product safe from infectious agents and the product obtainable by this method The present nanofiltration method is applicable on solutions of plasma-derived and recombinantly produced MBL. The MBL containing solution is subjected to a pre-treatment prior to the nanofiltration step. The nanofiltration is used for removal of viruses in general ... | 08/17/2010 |
| 7772182 | Stable suspension formulations of erythropoietin receptor agonists A suspension formulation for therapeutic use includes a non-aqueous, single-phase vehicle exhibiting viscous fluid characteristics and a particle formulation comprising an erythropoietin receptor agonist dispersed in the vehicle. ... | 08/10/2010 |
| 7767644 | Erythropoietin liquid formulation The invention relates to erythropoietin liquid formulations that are stable in storage and to a method for the production thereof. The invention particularly relates to erythropoietin liquid formulations, which contain at least four amino acids selected from the gro... | 08/03/2010 |
| 7767643 | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoi... | 08/03/2010 |
| 7759307 | Compositions for protection against superficial vasodilator flush syndrome, and methods of use Compositions for protection against SVFS syndromes are composed of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, an inventive olive kernel extract and a non-bovine sulfated proteoglycan, ... | 07/20/2010 |
| 7749960 | Osteoprotegerin in milk The present invention pertains to osteoprotegerin obtainable from milk sources, in particular human and bovine milk. The present invention also relates to the use thereof for preparing an ingestible preparation and/or a pharmaceutical composition, in particular to t... | 07/06/2010 |
| 7713931 | Cross-linked glycopeptide-cephalosporin antibiotics This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacteria... | 05/11/2010 |
| 7700551 | Hydrolysable polymeric FMOC-linker The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs. ... | 04/20/2010 |
| 7696163 | Erythropoietin: remodeling and glycoconjugation of erythropoietin The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. ... | 04/13/2010 |
| 7696164 | Substantially pure glycopeptide antibiotics AC-98-1 ; AC-98-2; AC-98-3; AC-98-4 and AC-98-5 The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism Streptomyces hygroscopicus. ... | 04/13/2010 |
| 7691810 | Method of producing recombinant antithrombin III composition The present invention provides a process for producing an antithrombin III composition comprising an antithrombin III molecule having complex type N-glycoside-linked sugar chains, wherein the complex type N-glycoside-linked sugar chains have a structure in which fuc... | 04/06/2010 |
| 7655621 | Cross-linked glycopeptide-cephalosporin antibiotics This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacteria... | 02/02/2010 |
| 7642234 | Beta-2-glycoprotein 1 is an inhibitor of angiogenesis The present disclosure provides a method of inhibiting angiogenesis within a tissue of interest by providing either intact or nicked β-Glycoprotein 1 (β2GP1) to cells associated with the tissue. The presence of β2GP1 inhibits angiogenesis within the tissue, in pa... | 01/05/2010 |
| 7638488 | Use of alpha-glucosidase inhibitors to treat alphavirus infections The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof a... | 12/29/2009 |
| 7638489 | Modulation of angiogenesis by The present invention relates to Bartonella henselae as a component of a pharmaceutical composition for the modulation of the angiogenesis; a nucleic acid molecule that is derived from the gene encoding the Bartonella henselae adhesin A protein (BadA),... | 12/29/2009 |
| 7629313 | Immunomodulatory polymeric antigens for treating inflammatory pathologies Provided are natural and synthetic immunomodulatory polymeric antigens (SPAs), compositions containing SPAs, and methods of using these natural and synthetic SPAs and compositions to prevent or treat inflammatory pathologies. ... | 12/08/2009 |
| 7618942 | Method of using broad-spectrum delta-endotoxins Disclosed are novel synthetically-modified B. thuringiensis chimeric crystal proteins having improved insecticidal activity and broader insect host range against coleopteran, dipteran and lepidopteran insects. Also disclosed are the nucleic acid segments enco... | 11/17/2009 |
| 7618941 | Treating degenerative joint disorders with tribonectins The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint. ... | 11/17/2009 |
